This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weiland, E.
Right arrow Articles by De Vries, A. A. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weiland, E.
Right arrow Articles by De Vries, A. A. F.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, June 2000, p. 2065-2075, Vol. 38, No. 6
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Monoclonal Antibodies Directed against Conserved Epitopes on the Nucleocapsid Protein and the Major Envelope Glycoprotein of Equine Arteritis Virus

Emilie Weiland,1,* Sylvia Bolz,1 Frank Weiland,1 Werner Herbst,2 Martin J. B. Raamsman,3 Peter J. M. Rottier,3 and Antoine A. F. De Vries3,dagger

Federal Research Centre for Virus Diseases of Animals, D-72076 Tübingen,1 and Institute for Hygiene and Infectious Diseases of Animals, D-35392 Giessen,2 Germany, and Virology Unit, Department of Infectious Diseases and Immunology, Veterinary Faculty, Utrecht University, 3584 CL Utrecht, The Netherlands3

Received 7 September 1999/Returned for modification 29 December 1999/Accepted 25 March 2000

We recently developed a highly effective immunization procedure for the generation of monoclonal antibodies (MAbs) directed against the porcine reproductive and respiratory syndrome virus (E. Weiland, M. Wieczorek-Krohmer, D. Kohl, K. K. Conzelmann, and F. Weiland, Vet. Microbiol. 66:171-186, 1999). The same method was used to produce a panel of 16 MAbs specific for the equine arteritis virus (EAV). Ten MAbs were directed against the EAV nucleocapsid (N) protein, and five MAbs recognized the major viral envelope glycoprotein (GL). Two of the EAV GL-specific MAbs and one antibody of unknown specificity neutralized virus infectivity. A comparison of the reactivities of the MAbs with 1 U.S. and 22 newly obtained European field isolates of EAV demonstrated that all N-specific MAbs, the three nonneutralizing anti-GL MAbs, and the weakest neutralizing MAb (MAb E7/d15-c9) recognized conserved epitopes. In contrast, the two MAbs with the highest neutralization titers bound to 17 of 23 (MAb E6/A3) and 10 of 23 (MAb E7/d15-c1) of the field isolates. Ten of the virus isolates reacted with only one of these two MAbs, indicating that they recognized different epitopes. The GL-specific MAbs and the strongly neutralizing MAb of unknown specificity (MAb E6/A3) were used for the selection of neutralization-resistant (NR) virus variants. The observation that the E6/A3-specific NR virus variants were neutralized by MAb E7/d15-c1 and that MAb E6/A3 blocked the infectivity of the E7/d15-c1-specific NR escape mutant confirmed that these antibodies reacted with distinct antigenic sites. Immunoelectron microscopy revealed for the first time that the antigenic determinants recognized by the anti-GL MAbs were localized on the virion surface. Surprisingly, although the immunofluorescence signal obtained with the neutralizing antibodies was relatively weak, they mediated binding of about three times as much gold granules to the viral envelope than the nonneutralizing anti-GL MAbs.


* Corresponding author. Mailing address: Federal Research Centre for Virus Diseases of Animals, Paul-Ehrlich-Strasse 28, D-72076 Tübingen, Germany. Phone: 49-7071-967204. Fax: 49-7071-967105. E-mail: E.Weiland{at}tue.bfav.de.

dagger Present address: Gene Therapy Section, Department of Molecular Cell Biology, Leiden University Medical Center, 2333 AL Leiden, The Netherlands.


Journal of Clinical Microbiology, June 2000, p. 2065-2075, Vol. 38, No. 6
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Wieringa, R., de Vries, A. A. F., van der Meulen, J., Godeke, G.-J., Onderwater, J. J. M., van Tol, H., Koerten, H. K., Mommaas, A. M., Snijder, E. J., Rottier, P. J. M. (2004). Structural Protein Requirements in Equine Arteritis Virus Assembly. J. Virol. 78: 13019-13027 [Abstract] [Full Text]  
  • Castillo-Olivares, J., Wieringa, R., Bakonyi, T., de Vries, A. A. F., Davis-Poynter, N. J., Rottier, P. J. M. (2003). Generation of a Candidate Live Marker Vaccine for Equine Arteritis Virus by Deletion of the Major Virus Neutralization Domain. J. Virol. 77: 8470-8480 [Abstract] [Full Text]  
  • Wieringa, R., de Vries, A. A. F., Rottier, P. J. M. (2003). Formation of Disulfide-Linked Complexes between the Three Minor Envelope Glycoproteins (GP2b, GP3, and GP4) of Equine Arteritis Virus. J. Virol. 77: 6216-6226 [Abstract] [Full Text]  
  • Wieringa, R., de Vries, A. A. F., Raamsman, M. J. B., Rottier, P. J. M. (2002). Characterization of Two New Structural Glycoproteins, GP3 and GP4, of Equine Arteritis Virus. J. Virol. 76: 10829-10840 [Abstract] [Full Text]